Skip to main content
CRBU
NASDAQ Life Sciences

Caribou's Q2 Loss Narrows to $24.3M; ATM Sales Add $18.3M While Cash Runway Holds at 12 Months

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$1.61
Mkt Cap
$159.681M
52W Low
$1.38
52W High
$3.535
52W Position info
17% above low
Off High info
54% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CRBU sits 17% above its 52-week low of $1.38.

Summary

Caribou Biosciences reported a narrower Q2 net loss of $24.3M and raised $18.3M via ATM sales, maintaining a 12-month cash runway.


Key Events · Earnings and Guidance · CRBU

  • Q2 Net Loss Narrows

    Net loss for Q2 2026 came in at $24.3M, down from $54.1M in Q2 2025, driven by lower R&D and G&A expenses following the 2025 restructuring.

  • ATM Sales Add $18.3M

    During Q2 2026, 9,006,276 shares were sold at an average price of $2.03 per share for gross proceeds of $18.3M; $75.2M remains available under the ATM program.

  • Cash Runway Maintained

    Cash, cash equivalents, and marketable securities totaled $113.8M as of June 30, 2026, sufficient to fund operations for at least 12 months.

  • Share Count Increases

    Shares outstanding rose to 105,995,653 as of June 30, 2026, from 95,143,690 at year-end 2025, reflecting ATM sales and equity compensation.


Analysis · CRBU · Life Sciences

The Q2 2026 10-Q reveals a net loss of $24.3 million, down from $54.1 million a year earlier, as lower R&D and G&A spending following last year's restructuring took hold. During the quarter, the company raised $18.3 million in gross proceeds through its at-the-market facility, selling 9.0 million shares at an average price of $2.03—a meaningful dilution for existing holders but one that keeps the cash runway at 12 months. With $113.8 million in cash and marketable securities, operations can be funded into mid-2027, though the ATM overhang remains: $75.2 million is still available for sale under the program.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CRBU was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $159.7M. The 52-week trading range was $1.38 to $3.54. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CRBU - Latest Insights

CRBU
Nov 05, 2026, 4:08 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.405
Real-time Price: $0.3601 info
Change: -$0.0449 (-11%) info
Market Cap: $39.098M info
CRBU
Nov 05, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.405
Real-time Price: $0.3601 info
Change: -$0.0449 (-11%) info
Market Cap: $39.098M info
CRBU
Oct 06, 2026, 4:37 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $0.705
Real-time Price: $0.3601 info
Change: -$0.3449 (-49%) info
Market Cap: $39.098M info
CRBU
Oct 06, 2026, 4:11 PM EDT
Source: Seeking Alpha
Importance Score:
9
Price at Filing: $1.14
Real-time Price: $0.3601 info
Change: -$0.7749 (-68%) info
Market Cap: $39.098M info
CRBU
Oct 06, 2026, 4:07 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.14
Real-time Price: $0.3601 info
Change: -$0.7749 (-68%) info
Market Cap: $39.098M info